MedTrace Logo

Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery

NCT00732563 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-10-18

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer.

PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.

Conditions

Interventions

DRUG

chemotherapy

Given IV and Orally

PROCEDURE

lymphadenectomy

Removal of lymph nodes

PROCEDURE

neoadjuvant therapy

Tumor reduction

PROCEDURE

quality-of-life assessment

Correlative Study

PROCEDURE

therapeutic conventional surgery

Treatment for cancer

PROCEDURE

thoracic surgical procedure

removal of tissue

RADIATION

fludeoxyglucose F 18

given IV

RADIATION

radiation therapy

undergoing radiotherapy

Sponsors & Collaborators

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Chukwumere E. Nwogu, MD · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-16
Primary Completion
2012-06-29
Completion
2017-07-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732563 on ClinicalTrials.gov